New phase 2 data showed that prostate cancer patients given a combination of Johnson & Johnson's (NYSE:JNJ) Erleada (apalutamide) and androgen deprivation therapy did not see an increase in prostate-...
Source LinkNew phase 2 data showed that prostate cancer patients given a combination of Johnson & Johnson's (NYSE:JNJ) Erleada (apalutamide) and androgen deprivation therapy did not see an increase in prostate-...
Source Link
Comments